Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mature dendritic cells transfected with human telomerase reverse transcriptase
- Development stage
- Phase 3
- Lead developer
- Oslo University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Mature dendritic cells transfected with human telomerase reverse transcriptase (hTERT) is an autologous dendritic cell-based cancer immunotherapy. The treatment involves harvesting dendritic cells from the patient, maturing them, and transfecting them ex vivo with mRNA encoding hTERT, a key catalytic subunit of telomerase that is highly overexpressed in various cancers, including glioblastoma and cancer stem cells. Upon reintroduction into the patient via intradermal injection, these antigen-presenting cells present hTERT peptides to the host immune system, stimulating a robust cytotoxic T-lymphocyte (CTL) response against telomerase-expressing tumor cells. This platform is being evaluated in clinical trials, such as the Phase II/III DEN-STEM trial sponsored by Oslo University Hospital, for the treatment of newly diagnosed glioblastoma in combination with standard chemoradiotherapy.
- Other names
- DEN-STEMdendritic cells transfected with hTERT mRNAdendritic cells transfected with human telomerase reverse transcriptase mRNAhTERT-transfected dendritic cell vaccinehTERT-transfected dendritic cellsmature dendritic cells transfected with hTERT
02
Targets
TERT (Telomerase)LAMP1 (Lysosomal-associated membrane protein 1)MHC I (MHC class I})γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on mature dendritic cells transfected with human telomerase reverse transcriptase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mature dendritic cells transfected with human telomerase reverse transcriptase.